Tianjin Development Holdings (HK:0882) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Tianjin Development Holdings’ subsidiary, Lisheng Pharmaceutical, has announced plans for a significant share repurchase program and a share award scheme. The repurchase program aims to buy back shares worth between RMB76.5 million and RMB153 million, while the award scheme will distribute restricted shares to key management. These moves are part of strategic maneuvers in the market and are subject to shareholder approval.
For further insights into HK:0882 stock, check out TipRanks’ Stock Analysis page.
